Time From Infection to Disease and Infectiousness for Ebola Virus Disease, a Systematic Review

Velásquez, Gustavo E.; Aibana, Omowunmi; Ling, Emilia J.; Diakite, Ibrahim; Mooring, Eric Q.; Murray, Megan

doi:10.1093/cid/civ531

Cited by 45 publications

(30 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…7A). Because L-threonine and VTDB plasma levels can predict outcomes several days prior to death (death occurs ~11–12 days from symptom onset, on average) (Velasquez et al, 2015) (Fig. 7A), these markers may be informative about discrete characteristics of infections leading to death, in contrast to events that return to baseline over time.…”

Section: Resultsmentioning

confidence: 99%

Multi-platform ’Omics Analysis of Human Ebola Virus Disease Pathogenesis

Eisfeld

Halfmann

Wendler

et al. 2017

Cell Host & Microbe

103

113

View full text Add to dashboard Cite

SUMMARY The pathogenesis of Human Ebola virus disease (EVD) is complex. EVD is characterized by high levels of virus replication and dissemination, dysregulated immune responses, extensive virus- and host-mediated tissue damage, and disordered coagulation. To clarify how host responses contribute to EVD pathophysiology, we performed multi-platform ‘omics analysis of peripheral blood mononuclear cells and plasma from EVD patients. Our results indicate that EVD molecular signatures overlap with those of sepsis, imply that pancreatic enzymes contribute to tissue damage in fatal EVD, and suggest that EBOV infection may induce aberrant neutrophils whose activity could explain hallmarks of fatal EVD. Moreover, integrated biomarker prediction identified putative biomarkers from different data platforms that differentiated survivors and fatalities early after infection. This work reveals insight into EVD pathogenesis, suggests an effective approach for biomarker identification, and provides an important community resource for further analysis of human EVD severity.

show abstract

Section: Resultsmentioning

confidence: 99%

Multi-platform ’Omics Analysis of Human Ebola Virus Disease Pathogenesis

Eisfeld

Halfmann

Wendler

et al. 2017

Cell Host & Microbe

103

113

View full text Add to dashboard Cite

show abstract

“…Other extensions could include modelling the risk of pathogen importation from other geographical locations [13], accounting for temporal or spatial variation in the surveillance sensitivity [8], allowing for the possibility of introductions of immunologically naive hosts resulting from population displacement [49], or explicitly including dry (uninfectious) and wet (infectious) Ebola symptoms [29,50]. Additional refinement would be needed to estimate the confidence in end-of-outbreak declarations when diseases that royalsocietypublishing.org/journal/rstb Phil.…”

Section: Discussionmentioning

confidence: 99%

Rigorous surveillance is necessary for high confidence in end-of-outbreak declarations for Ebola and other infectious diseases

Thompson

Morgan

Jalava

2019

Phil. Trans. R. Soc. B

View full text Add to dashboard Cite

One contribution of 16 to a theme issue 'Modelling infectious disease outbreaks in humans, animals and plants: epidemic forecasting and control'. Subject Areas: computational biology, ecology, health and disease and epidemiology, systems biologyThe World Health Organization considers an Ebola outbreak to have ended once 42 days have passed since the last possible exposure to a confirmed case. Benefits of a quick end-of-outbreak declaration, such as reductions in trade/travel restrictions, must be balanced against the chance of flare-ups from undetected residual cases. We show how epidemiological modelling can be used to estimate the surveillance level required for decision-makers to be confident that an outbreak is over. Results from a simple model characterizing an Ebola outbreak suggest that a surveillance sensitivity (i.e. case reporting percentage) of 79% is necessary for 95% confidence that an outbreak is over after 42 days without symptomatic cases. With weaker surveillance, unrecognized transmission may still occur: if the surveillance sensitivity is only 40%, then 62 days must be waited for 95% certainty. By quantifying the certainty in end-of-outbreak declarations, public health decision-makers can plan and communicate more effectively.This article is part of the theme issue 'Modelling infectious disease outbreaks in humans, animals and plants: epidemic forecasting and control'. This issue is linked with the earlier theme issue 'Modelling infectious disease outbreaks in humans, animals and plants: approaches and important themes'.

show abstract

“…In the rhesus macaque natural history study, the incubation period is defined as the time from virus exposure to fever onset. b Source: [10]; c Source: [11]; d Source: [12]; e Sources: [13][14][15]; f Source: [16] g Data for humans are from the following sources: [11,[17][18][19][20][21]. h Data for humans are from the following sources: [20,[22][23][24][25][26][27][28][29][30][31].…”

Section: Rhesus Im/ebov Disease Compared To Human Evdmentioning

confidence: 99%

Characterization of Ebola Virus Disease (EVD) in Rhesus Monkeys for Development of EVD Therapeutics

Warren

Zumbrun

Weidner

et al. 2020

Viruses

View full text Add to dashboard Cite

Recent Ebola virus (EBOV) outbreaks in West Africa and the Democratic Republic of the Congo have highlighted the urgent need for approval of medical countermeasures for treatment and prevention of EBOV disease (EVD). Until recently, when successes were achieved in characterizing the efficacy of multiple experimental EVD therapeutics in humans, the only feasible way to obtain data regarding potential clinical benefits of candidate therapeutics was by conducting well-controlled animal studies. Nonclinical studies are likely to continue to be important tools for screening and development of new candidates with improved pharmacological properties. Here, we describe a natural history study to characterize the time course and order of progression of the disease manifestations of EVD in rhesus monkeys. In 12 rhesus monkeys exposed by the intramuscular route to 1000 plaque-forming units of EBOV, multiple endpoints were monitored for 28 days following exposure. The disease progressed rapidly with mortality events occurring 7–10 days after exposure. Key disease manifestations observed consistently across the infected animals included, but were not limited to, viremia, fever, systemic inflammation, coagulopathy, lymphocytolysis, renal tubular necrosis with mineralization, and hepatocellular degeneration and necrosis.

show abstract

Time From Infection to Disease and Infectiousness for Ebola Virus Disease, a Systematic Review

Cited by 45 publications

References 25 publications

Multi-platform ’Omics Analysis of Human Ebola Virus Disease Pathogenesis

Multi-platform ’Omics Analysis of Human Ebola Virus Disease Pathogenesis

Rigorous surveillance is necessary for high confidence in end-of-outbreak declarations for Ebola and other infectious diseases

Characterization of Ebola Virus Disease (EVD) in Rhesus Monkeys for Development of EVD Therapeutics

Contact Info

Product

Resources

About